Member Info for easyp

Investec now say 225p why?

6.9% seems a bit sharp, rumours? As it happens I would happily buy more if they were in the 220s.

This is an interesting summary from a couple of complex engineering papers doing the rounds. Plexus hope to sell more equipment as a means to stop natural gas leaks because of its worrying green house potential. A new direction for Plexus and I think a promising one for those able to await orders and progress.

"Recent reports in the press and media question the clean reputation of Natural Gas as an alternative energy source, as compared to Oil and Coal. Whereas Oil and Coal emit minimal CO2 to the environment during production, transportation and storage, this cannot be said of Natural gas and Methane. To project the reputation of Natural Gas, as the preferred hydrocarbon energy source, operators are rallying to improve gas leakage rates, from production to consumer. Containment of Natural Gas and particularly Methane requires metal-to-metal sealing, which can only succeed properly, if circumstances enable adherence to the Hertzian Stress Theory (HST) for metal seals. The proposed paper addresses these issues and explains why conventional sealing solutions are not able to satisfy HST conditions, whereas alternative and proven technology, which requires and deserves recognition, has been available for decades and which has been qualified following procedures that deliver "real world" results."

Thanks for an interesting post, I am a little more optimistic. My view (might be wrong) is that the drug did work quite well at Phase 3 but oddly the placebo patients appeared to do well enough that statistically the trial appeared inconclusive. The extension trial I think will be positive for those still taking Lupizor what has not been scientifically explained is why the placebo appeared to work so well?

I also have shared in the growing pains of biotechs over a longish period of investing and accept some do not make it full stop, some suffer setbacks and come good while a few fly through trials. IMM has suffered a setback late in the game, disappointing but not fatal to Lupizor.

I think it likely hence invested although down a little despite buying more. But why, is hope enough when investing hard earned cash?

The oil supplies from the gulf vulnerable to sanctions and military action while Colombia has oil relatively close to the surface on shore, not very good infrastructure but a pipeline or two and is close to the USA a major consumer.

What about the US shale industry? Well they have logistic issues too and while the USA has enough natural gas it still needs certain grades of oil to refine. Finally, despite South America being a basket case of corruption and failed economies it will one day turn itself around and want more energy.

Suspect what will really drive the sp is a bid from a major or another player trying to consolidate the field.

In a world teetering on trade wars and collapse of the Turkish economy the price of silver and gold continues to slump as does the share price of the miners like Hecla. Truly a mad world or is it? More likely the silver and gold market has been artificially depressed by paper trades for years in order to protect fiat currencies.

I am inclined to hold what I have and trickle invest in silver, gold and uranium shares. Will it pay off? Uranium certainly on the up.

"For investors in start-up biotech companies, patience is less a virtue than a necessity. Companies can sometimes wait a decade or more to begin generating revenue, with new products undergoing lengthy laboratory testing before they can enter clinical trials. At any point, a weak or inconclusive result can send scientists and executives scurrying back to square one.

The recent news that UK-based GW Pharmaceuticals had received approval from the Food and Drug Administration for the first cannabis-derived medicine to be made available in the US — 20 years after the company was founded — is a reminder that the spoils can eventually be large for those willing to keep the faith.

Other less high-profile companies have also gone through the difficult process of bringing products to market, to reach the sunny uplands of revenue-generation.

Diurnal
Diurnal started life in 2004 as a spinout from the University of Sheffield, with a focus on developing treatments for endocrine diseases, with the exception of diabetes.

About two months ago it became revenue-generating for the first time, after winning regulatory approval for Alkindi, a medicine to treat a rare disease called paediatric adrenal insufficiency. The drug was launched in Germany in the middle of May. It is now awaiting the results of a late-stage trial of another product, Chronocort, for the treatment of adrenal insufficiency in adults.

The company went public in December, 2015, raising £30m, and recently raised a further £10.5m. Its market capitalisation is £108.9m.

Explaining how the company carved out its own niche, Martin Whitaker, chief executive, said: “Diabetes is, of course, a huge burden across the globe, but it’s actually very well served by all the large pharmaceutical companies. So, Diurnal’s focus is very much on all the other diseases that perhaps have been neglected by big pharma.”

Mr Whitaker has just passed his 10-year anniversary at the company: proof, he said wryly, “that developing pharmaceuticals does take a long time”."

"For investors in start-up biotech companies, patience is less a virtue than a necessity. Companies can sometimes wait a decade or more to begin generating revenue, with new products undergoing lengthy laboratory testing before they can enter clinical trials. At any point, a weak or inconclusive result can send scientists and executives scurrying back to square one.

The recent news that UK-based GW Pharmaceuticals had received approval from the Food and Drug Administration for the first cannabis-derived medicine to be made available in the US — 20 years after the company was founded — is a reminder that the spoils can eventually be large for those willing to keep the faith.

Other less high-profile companies have also gone through the difficult process of bringing products to market, to reach the sunny uplands of revenue-generation.

Diurnal
Diurnal started life in 2004 as a spinout from the University of Sheffield, with a focus on developing treatments for endocrine diseases, with the exception of diabetes.

About two months ago it became revenue-generating for the first time, after winning regulatory approval for Alkindi, a medicine to treat a rare disease called paediatric adrenal insufficiency. The drug was launched in Germany in the middle of May. It is now awaiting the results of a late-stage trial of another product, Chronocort, for the treatment of adrenal insufficiency in adults.

The company went public in December, 2015, raising £30m, and recently raised a further £10.5m. Its market capitalisation is £108.9m.

Explaining how the company carved out its own niche, Martin Whitaker, chief executive, said: “Diabetes is, of course, a huge burden across the globe, but it’s actually very well served by all the large pharmaceutical companies. So, Diurnal’s focus is very much on all the other diseases that perhaps have been neglected by big pharma.”

Mr Whitaker has just passed his 10-year anniversary at the company: proof, he said wryly, “that developing pharmaceuticals does take a long time”."

I would be delighted to see how Labour could just magic out of thin air 22% of the UKs electricity demand in 100 days. I put this Labour claim with all the others like "paying off all student debt" in the too difficult box.

http://gridwatch.co.uk/

http://www.lse.co.uk/sharecast-news-article.asp?ArticleCode=27859934&ArticleHeadline=ryanair_grounds_400_flights_as_pilots_walk_out_in_5_european_states

While Flybe does not compete directly on many routes the strikes should help Flybe seat occupancy and profit margins this year as passengers seek alternative arrangements. Some might even like the Flybe offering!

Interesting article which mentions BKY in passing.

https://seekingalpha.com/article/4196333-can-cameco-corner-uranium-spot-market?li_source=LI&li_medium=liftigniter-widget

Possibly more given that the directors own a chunk of the shares.

Potentially, some good news for Uranium demand but a way off yet.

Developers of “mini” nuclear reactors in the UK should be offered the same subsidies as those provided to offshore wind to help commercialise the nascent industry, an independent group of experts has recommended.

The proposal is among several contained in a report by an expert finance working group appointed by the government last year to advise on how small nuclear reactor projects, which range from micro to 600 megawatt reactors, could raise private investment. Large reactors typically generate more than 1,000 megawatts.

The UK is one of the few western nations committed to building new nuclear power stations, and the development of a new generation of small atomic reactors is seen as crucial to the industry’s future as it grapples to stay competitive against the rapidly falling costs of renewables, including solar and wind.

The government in June committed up to £56m to kick-start research and development into the most advanced types of small reactor technologies, most of which will not be commercially available until the late 2020s.

Richard Harrington, energy minister, said the report by the expert finance working group “recognises the opportunity presented by small nuclear reactors”.

“Advanced nuclear technologies provide a major opportunity to drive clean growth and could create high-skilled, well-paid jobs around the country as part of our modern industrial strategy,” he added.

I was concerned over the sp and graham kindly responded with some info. Holding on for developments!

"As you know we are focusing on a number of initiatives and must admit that director purchases have not been one of them. One of the reasons is that the directors/founders still control a large % of Plexus and the market has indicated that over time that being lower to increase liquidity would not be a bad thing.

The other issue we have is that with initiatives and news flow it means there are quite a number of close periods whereby directors cannot deal in the company's shares, but we would hope that over time further Plexus POS-GRIP® IP driven opportunities will be the engine behind the share price rather than short term boosts."

Might it be that many small investors are still on board but selling and taking profits on good news while the institutions are starting to buy with a mind to the future? I am a small PI and have followed OXB for years, way back when Motley Fool was free etc and was tempted to sell but realised there was more to come others may want their gains crystallised into cash?

Yep encouraging progress over the past week. COS seems to be in favour again with small investors.

It could mean the brokers are becoming millionaires as they buy shares here and transfer them to a hungry Spanish Market for a 500% margin? Becoming concerned but not selling!

Glad I sold Stobart and remain invested here. I disagree that the proposal would not have been in the interests of the Stobart shareholders. Realistically, it seems unlikely a bid will materialise from Stobart until the court case is settled if at all so the Flybe share price has to fly on its own business merits rather than bid speculation.

You were right. Did not sell so having reassessed will average down a little and hold at least until year end.

Some of you probably wonder why I mention Energy Fuels so much on this board, this is an extract from their Q2 results and the prices are interesting. Assuming BKY is producing next year at the prices below what would the profit margin look like?

"500,000 pounds of U3O8 deliveries were completed by the Company for the three months ended June 30, 2018 at an average realized price of $53.55 per pound. On April 1, 2018, the Company delivered 400,000 lbs. of U3O8 into long-term sales contracts at the price of $61.30 per pound, resulting in the receipt of over $24.5 million on May 1, 2018. In addition, on June 15, 2018 the Company delivered 100,000 lbs. of U3O8 into a spot contract at $22.57 per pound."